期刊文献+

喹硫平辅助治疗难治性抑郁症的临床观察 被引量:4

下载PDF
导出
摘要 目的探讨喹硫平辅助治疗难治性抑郁症临床效果及安全性。方法选取我院2010年2月至2012年2月收治难治性抑郁症患者90例,采用随机数字表法分为两组,其中对照组90例,采用文拉法辛口服,首次剂量为75mg/d,1周后增至150mg/d,喹硫平辅助组90例,在对照组基础上加用喹硫平口服,首次剂量为50mg/d,1周后增至250mg/d;疗程均为2个月;比较两组患者临床治疗总有效率,治疗前后汉密尔顿抑郁量表(HAMD)评分及不良反应发生情况等。结果喹硫平辅助组患者临床治疗总有效率明显优于对照组(P<0.05);对照组与喹硫平辅助组患者治疗后HAMD评分较治疗前均明显改善,且喹硫平辅助组患者治疗后HAMD评分改善程度明显高于对照组(P<0.05);同时对照组与喹硫平辅助组患者恶心呕吐、口干、头晕、视物模糊及静坐不能等不良反应发生率组间比较无显著差异(P>0.05)。结论喹硫平辅助治疗难治性抑郁症能够有效缓解临床症状,改善生活质量,且无严重不良反应。
作者 章丽萍
出处 《中国医药指南》 2013年第2期521-522,共2页 Guide of China Medicine
  • 相关文献

参考文献5

  • 1余柳霞,蒋庆飞,朱跃华,贾媛,黄蕙舜.帕罗西汀合并喹硫平治疗难治性抑郁症对照研究[J].现代中西医结合杂志,2007,16(23):3302-3303. 被引量:3
  • 2刘力,刘盈,黄永进,毕红希.喹硫平辅助治疗难治性抑郁症58例[J].医药导报,2007,26(11):1308-1310. 被引量:13
  • 3Denys D,deGeus F, van Megen HJ,et al.A double-blind,randomized, placebo-controlled trial of quetiapine addition in patients withobsessive-compulsive disorder refractory to serotonin reuptake inhibitors[J].J Clin Psychiatry,2004,65(8): 1040-1048. 被引量:1
  • 4Kordon A,Wahl K,Koch N,et al.Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder:a double-blind,randomized,placebo-controlled study[J].JClin Psychopharmaco,2008,28(5):550-554. 被引量:1
  • 5Bloch MH,Landeros-Weisenberger A,Kelmendi B,et al.Asystematic review:antipsychotic augmentation with treatment refractory obsessive-compulsivedisorder[J].Mol Psychiatry,2006,11(7):622- 632. 被引量:1

二级参考文献14

  • 1王慧芳,彭代辉,白艳乐,江开达.奎硫平治疗女性精神分裂症患者的疗效[J].上海精神医学,2005,17(2):83-86. 被引量:9
  • 2[1]Fontaine R,Ontiveros A,Eilie R,et al.A double-blind comparison of nafazodone,imipramine,and placebo in major depression[J].Clin Psychiatry,1994,55 (6):234-241 被引量:1
  • 3[5]Sajatovic M,Mullen JA,Sweitzer DE.Efficacy of quetiapoine and riperidone against deressive symptoms in outpatients with psychosis[J].J Clin Psychiatry,2002,63(12):1156-1163 被引量:1
  • 4[6]Copollow DL,Link CG,Kowalcyk B.A multicentre,double-blind randomized comparison of quetiapine (IcI 204,636,seroquel) and halopridol in schizophrenia[J].Psychol Med,2000,30:95-105 被引量:1
  • 5PAPAKOSTAS G I. Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder [ J ]. Essent Psychopharmacol, 2005,6(4) :209 - 220. 被引量:1
  • 6GEFVER T O, LUNDBERG T, WIESEGREN I M, et al. D2 and 5-HT2A receptor occupancy of different doses of quetiapine in Schizophrenia: a PET study [ J ]. Eur Neuropsychopharmacol,2001,11 : 105 - 110. 被引量:1
  • 7GOLDSTEIN J, ARVANITI S L. ICI 204,636( seroquel ) : a dibenothiazepine atypical antipsyehotie : review of preelinieal pharmacology and highlights of phase 2 clinicaltrials[J]. CNS Drug Rev,1995,1 : 50 -73. 被引量:1
  • 8SIMON J S, NEMEROFF C B. Aripiprazole augumention of antidepressants for the treatment of partially responding and non responding patients with major depressive disorder[ J ]. J Clin psychiatry, 2005,66(10) : 1216 - 1220. 被引量:1
  • 9THASE M E, CORYA S A, OSUNTOKUN O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine , and fluoxetine in treatmentresistant major depressive [ J]. J Clin Psychiatry,2007, 68 (2) :224-236. 被引量:1
  • 10RAOPAPORT A,GHARABAWI G M, CANUSO C M, et al. Effects of risperidone augmentation in patients with treatmentresistant depression: Results of open-label treatment followed by double-blind continuation [ J ]. Neuropsychopharmacology, 2006, 31(11) :2505 -2513. 被引量:1

共引文献14

同被引文献27

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部